Ekso Bionics Stock to Reverse Split on Monday, June 2nd (NASDAQ:EKSO)

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) are going to reverse split on Monday, June 2nd. The 1-15 reverse split was announced on Monday, May 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, May 30th.

Ekso Bionics Trading Up 0.4%

Shares of Ekso Bionics stock opened at $0.28 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The firm has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.55. Ekso Bionics has a 1 year low of $0.23 and a 1 year high of $1.53. The stock has a market cap of $9.87 million, a PE ratio of -0.43 and a beta of 1.09.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, May 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $4.62 million. Equities research analysts predict that Ekso Bionics will post -0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EKSO has been the subject of several recent research reports. HC Wainwright reduced their target price on shares of Ekso Bionics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Wall Street Zen initiated coverage on shares of Ekso Bionics in a report on Thursday. They issued a “hold” rating for the company. Finally, Lake Street Capital cut their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC raised its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,042,382 shares of the company’s stock after buying an additional 316,733 shares during the period. Armistice Capital LLC owned about 7.03% of Ekso Bionics worth $823,000 at the end of the most recent quarter. 6.42% of the stock is owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.